

Resource Summary Report

Generated by ASWG on Aug 3, 2026

Genentech

RRID:SCR_003997

Type: Tool

Proper Citation

Genentech (RRID:SCR_003997)

Resource Information

URL: <http://www.gene.com/>

Proper Citation: Genentech (RRID:SCR_003997)

Description: A biotechnology corporation that uses human genetic information to discover, develop, manufacture and commercialize medicines to treat patients with serious or life-threatening medical conditions.

Abbreviations: Genentech

Synonyms: Genentech Inc, F. Hoffmann-La Roche Ltd / Genentech

Resource Type: commercial organization

Keywords: drug, genetic, medicine, biotechnology, oncology, immunology, tissue growth, tissue repair, neuroscience, infectious disease, microbiology, medical imaging

Related Condition: Infectious disease, Cancer

Resource Name: Genentech

Resource ID: SCR_003997

Alternate IDs: nlx_158417

Record Creation Time: 20220129T080222+0000

Record Last Update: 20260801T190229+0000

Ratings and Alerts

No rating or validation information has been found for Genentech.

No alerts have been found for Genentech.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 3306 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#).

Pourmal S, et al. (2025) Autoinhibition of dimeric NINJ1 prevents plasma membrane rupture. *Nature*, 637(8045), 446.

Haap-Hoff A, et al. (2025) RNAi library screening reveals G?1, Casein Kinase 2 and ICAP-1 as novel regulators of LFA-1-mediated T cell polarity and migration. *Immunology and cell biology*, 103(1), 73.

Kottana RK, et al. (2025) A method to quantitatively characterize the formation and dissociation of tumor cell clusters using light transmission aggregometry. *Molecular oncology*, 19(1), 37.

Armstrong D, et al. (2025) MAGE-A4 induces non-small cell lung cancer and tumor-promoting plasma cell accumulation. *Science advances*, 11(7), eads4227.

Zhang X, et al. (2025) S100A12 triggers NETosis to aggravate myocardial infarction injury via the Annexin A5-calcium axis. *Nature communications*, 16(1), 1746.

Garcia-Knight MA, et al. (2025) Circulating neutralizing antibodies and SARS-CoV-2 variant replication following postvaccination infections. *JCI insight*, 10(5).

Zhang Y, et al. (2025) Pyroptosis of pulmonary fibroblasts and macrophages through NLRP4 inflammasome leads to acute respiratory failure. *Cell reports*, 44(4), 115479.

Villa S, et al. (2025) BiDAC-dependent degradation of plasma membrane proteins by the endolysosomal system. *Nature communications*, 16(1), 4345.

Garcia-Pena CM, et al. (2025) Oculomotor axons use external and autocrine Slit signals for fasciculation, navigation, branching, and connectivity in mouse embryos. *Research square*.

Reader CS, et al. (2025) The tetravalent, bispecific properties of FS118, an anti-LAG-3/PD-L1 antibody, mediate LAG-3 shedding from CD4 + and CD8 + tumor-infiltrating lymphocytes. *Anti-cancer drugs*, 36(6), 447.

Ivanisenko NV, et al. (2025) Oligomerised RIPK1 is the main core component of the CD95 necrosome. *The EMBO journal*, 44(11), 3231.

Arceo T, et al. (2025) Impact of positive control binding properties on anti-drug antibody assay performance. *Bioanalysis*, 17(11), 701.

Rosas IO, et al. (2025) Long-Term Clinical Outcomes of Adults Hospitalized for COVID-19 Pneumonia. *Emerging infectious diseases*, 31(6), 1158.

Pearlman JA, et al. (2025) Phase I Study of the Anti-interleukin 33 Fragment Antigen-Binding Region RO7303359 in Geographic Atrophy Secondary to Age-Related Macular Degeneration. *Ophthalmology science*, 5(5), 100800.

Wang L, et al. (2025) Evaluation of chicken chorioallantoic membrane model for tumor imaging and drug development: Promising findings. *Animal models and experimental medicine*, 8(2), 287.

Capuani S, et al. (2025) Modeling of a Bioengineered Immunomodulating Microenvironment for Cell Therapy. *Advanced healthcare materials*, 14(5), e2304003.

Angelicola S, et al. (2025) PD-L1 and IFN- γ modulate Non-Small Cell Lung Cancer (NSCLC) cell plasticity associated to immune checkpoint inhibitor (ICI)-mediated hyperprogressive disease (HPD). *Journal of translational medicine*, 23(1), 2.

Lopez J, et al. (2025) Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial. *Nature medicine*, 31(1), 152.

Scalambra L, et al. (2025) Targeting PCSK9, through an innovative cVLP-based vaccine, enhanced the therapeutic activity of a cVLP-HER2 vaccine in a preclinical model of HER2-positive mammary carcinoma. *Journal of translational medicine*, 23(1), 136.

Hendricks AL, et al. (2025) Bacterial biofilm-derived H-NS protein acts as a defense against Neutrophil Extracellular Traps (NETs). *NPJ biofilms and microbiomes*, 11(1), 58.